Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

Wyeth is now a wholly owned subsidiary of Pfizer6 enrolled

Overview

This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

SKI-606DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Healthy men, aged 18 to 50 years.

Locations (1)

Unnamed facility

Tacoma, Washington, United States

Outcomes

Primary Outcomes

Mass Balance and Metabolic Disposition

Time frame: 10 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.